We are a late-stage biotechnology company pioneering the development of a novel class of TCR (T cell receptor) bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including […]

Note: This is the third blank-check company put together by Barry S. Sternlicht, the founder and former chairman and CEO of Starwood Hotels & Resorts Worldwide. (This blank-check company is incorporated in the Cayman Islands.) From the prospectus: Our sponsor, Mustang Sponsor LLC, is an affiliate of Jaws Estates Capital, the family office of Barry S. […]

We are a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. We […]

We are a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the immune system’s strength by activating and recruiting myeloid cells to […]

Vor Biopharma’s mission is to develop transformative treatments for patients suffering from hematological malignancies. We are a clinical-stage cell therapy company combining a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. For many patients, the only way to achieve durable remission or a cure […]

We are a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. We aim to inhibit the inflammatory responses by changing the metabolic processes in target cells. Through our […]

We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as […]

We intend to focus on industries that complement our management team’s background and to capitalize on the ability of our management team and the broader Noble Rock Advisors platform to identify, acquire and operate a business in the software and tech-enabled services sectors. We will seek to acquire one or more businesses with an aggregate enterprise […]

We were created to take advantage of transformative macro and micro trends occurring domestically and internationally, driven by the impact of technology on how work is executed, facilitated and enhanced.  Our executive co-chairman, Doug Atkin, is a co-founder and managing partner at Communitas Capital, a venture fund he launched in 2018 with Tom Glocer (former CEO […]

We currently intend to concentrate our efforts in identifying businesses in the industrial technology, advanced materials or specialty chemicals industries (collectively, “Advanced Industrials”). A common theme across these sectors is the application of technology to make industrial processes more profitable, faster, more sustainable, less capital-intensive and less complex. Specifically, we intend to identify businesses that […]